COVID-19 Treatments

CMH offers monoclonal antibody infusion treatments and antiviral medications for patients with COVID-19.

Woman wrapped in a blanket with a cup of tea in her hand

The U.S. Food and Drug Administration (FDA) has approved the following outpatient treatment methods:

  • Sotrovimab, a monoclonal anibody, for the treatment of mild to moderate COVID-19 in adults and pediatric patients who are 12 years of age and older weighing at least 40 kg, and who are at high risk for progressing to severe COVID-19 and/or hospitalization. 
  • Paxlovid (nirmatrelvir/ritonavir), an oral antiviral, for the treatment of mild to moderate COVID-19 in adults and pediatric patients who are 12 years of age and older weighing at least 40 kg, and who are at high risk for professing to severe COVID-19 and/or hospitalization.
  • Molnupiravir, an oral antiviral, for the treatment of mild to moderate COVID-19 in adults with positive results of direct SARS-CoV-2 viral testing who are 18 years of age, and who are at high risk for progressing to severe COVID-19 and/or hospitalization.
  • Remdesivir, an oral antiviral, for adults and certain pediatric patients with COVID-19. Not recommended for severe renal or liver failure. 

These treatments must be given within a certain number of days from symptom onset. Paxlovid and molnupiravir within five (5) days; remdesivir within seven (7) days; and sotrovimab within 10 days.

Learn more about these treatments at fda.gov.

Who Qualifies?

Monoclonal antibody treatment is NOT authorized for use in patients:

  • Who are hospitalized due to COVID-19, or
  • Who require oxygen therapy due to COVID-19, or
  • Who require an increase in baseline oxygen flow rate due to COVID-19 in those on chronic oxygen therapy due to underlying non-COVID-19 related comorbidity.

Oral antivirals are NOT authorized for use in patients:

  • Requiring hospitalization due to COVID-19
  • For pre-exposure or post-exposure prophylaxis
  • For longer than 5 days of therapy

How can I access these treatments?

All COVID-19 treatments are currently under strict allocation through DHSS. These treatments are available by prescription only. 

Patients with a test-confirmed COVID-19 diagnosis that are experiencing symptoms may be eligible for outpatient treatment options, based on when your symptoms started. Please contact your primary care provider to see what treatment options may be available.   

Monoclonal Antibodies Infusion

Monoclonal antibodies are administered via IV infusion over at least 30-60 minutes. Patients who are approved for therapy will be contacted by a CMH Infusion Center staff member to set up an appointment. Patients will receive instructions for arrival and check-in at that time. Patients will be provided with the EUA Fact Sheet before infusion. Patients are required to stay at the infusion site for one hour of observation following their infusion.

CMH Infusion Center

Monoclonal antibody infusions are scheduled Monday-Friday, 8 a.m. – 4 p.m. Call 417-328-4300 to find out if you are a candidate for a monoclonal antibody infusion for the treatment of mild to moderate COVID-19.